Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 26, 2019 - Issue 4
246
Views
15
CrossRef citations to date
0
Altmetric
Articles

Founder effect of the Glu89Gln TTR mutation in the Bulgarian population

, , , , , , , & show all
Pages 181-185 | Received 31 Aug 2018, Accepted 18 Jun 2019, Published online: 29 Jul 2019
 

Abstract

Hereditary transthyretin amyloidosis is an autosomal dominant genetic disorder caused by missense mutations in the TTR gene resulting in amyloid formation of the transthyretin protein. Depending on the system affection, the manifestations may be different and high heterogeneity in the penetrance is observed. An endemic region in Bulgaria exists where the TTR mutation Glu89Gln is found with high frequency. This is a rare mutation and was probably introduced in the population by a common ancestor. This phenomenon, called “founder effect” was proved in carrier families by haplotype analysis of microsatellite markers showing linkage disequilibrium. Allele frequencies were analyzed and haplotype reconstruction was done with Arlequin v.3.01 software. The common ancestry of the carriers was demonstrated using additional data for their genealogies and microsatellite data from a control group of non-affected individuals. The results show that the mutation Glu89Gln is linked to one haplotype, called “hypothetical founder haplotype” which was compared to published haplotype data from other European patients and no similarity was found. Further population genetics studies of carriers of the Glu89Gln mutation from other endemic regions are required in order to clarify the geographical distribution of the mutation.

Disclosure statement

The authors report no conflict of interest.

Additional information

Funding

The study was supported by Pfizer in the context of Investigator-Initiated Project Research Grant, No WI220557, Pfizer Luxemburg Sarl, Bulgaria Branch, 15.11.2016.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.